Labcorp Holdings Inc. LH

Full chart Compare
Set alert

Price alert · LH

All alert types
353.92 USD -1.67 (-0.47%)

At closeNov 3, 2026, 5:05 PM EST

353.93 +0.01 +0.00%

After hours · Nov 3, 5:05 PM ET

350.66 Day range 358.53
244.52 52-week range 371.00
YTD
+41.07%
1 year
+37.26%
Market cap
28.74B
Revenue (ttm)
14.59B
Profit margin
6.88%
EPS (ttm)
12.20
Shares out
81.20M
P/E ratio
29.01
Forward P/E
18.07
Dividend
2.88 (0.81%)
Ex-dividend date
Nov 23, 2026
YTD return
+41.07%
1-year return
+37.26%
Volume
704.62K
Avg volume
716.85K
Open
353.70
Previous close
355.59
Day's range
350.66 – 358.53
52-week range
244.52 – 371.00
Beta
0.83
Analysts
Buy
Price target
382.25 (+8.0%)
Earnings date
Feb 16, 2027

2Y +126.75 (+55.80%)

200250300350Jan 25Jun 25Nov 25Mar 26Aug 26353.92

Key statistics

Enterprise value
35.48B
PEG ratio
1.57
Price / sales
1.97
Price / book
3.25
Dividend yield
0.81%
Payout ratio
23.61%
Revenue growth
6.90%
Free cash flow
1.06B
Total cash
261.80M
Total debt
6.85B
Return on equity
11.44%
Short % of float
3.16%
50-day average
323.61
200-day average
287.98

Financials — quick view

All financials
LH Revenue — quarterly 3.81B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LH Net income — quarterly 262.80M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
LH EPS — quarterly 3.24
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

LH recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 16, 2027Dec 30, 20264.50———
Oct 28, 2026Sep 30, 20264.644.78+0.14+3.02%
Jul 30, 2026Jun 30, 20264.784.99+0.21+4.39%
Apr 30, 2026Mar 31, 20264.114.25+0.14+3.41%
Feb 17, 2026Dec 31, 20253.954.07+0.12+3.04%
Oct 28, 2025Sep 30, 20254.134.18+0.05+1.21%

Upgrades / downgrades

LH analyst upgrades and downgrades
DateFirmActionFromTo
Oct 29, 2026UBSmainBuyBuy
Oct 29, 2026BarclaysmainEqual-WeightEqual-Weight
Oct 29, 2026Truist SecuritiesmainBuyBuy
Oct 29, 2026BairdmainOutperformOutperform
Sep 21, 2026Truist SecuritiesmainBuyBuy
Sep 11, 2026UBSmainBuyBuy

About Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
labcorp.com

News

Your note

Sign in to keep a note on LH — it syncs with the Stock Master app.

Insider holders

LH insider holders
InsiderRelationLatest transactionDateShares held
ANDERSON KERRII BDirectorSaleAug 16, 20266,851
BERBERIAN LANCE VOfficerStock Award(Grant)Mar 26, 202518,652
CAVENEY BRIAN JOfficerStock Award(Grant)Mar 25, 202636,491
EISENBERG GLENN AOfficerStock Award(Grant)Mar 26, 202537,920
KONG GARHENGDirectorConversion of Exercise of derivative securityFeb 10, 202613,739
NEUPERT PETER MDirectorConversion of Exercise of derivative securityFeb 10, 202613,784

Institution ownership

LH institution ownership
Holder% heldSharesValueReported
Blackrock Inc.8.10%6,574,2612.33BJun 29, 2026
Vanguard Capital Management LLC6.60%5,362,2541.90BJun 29, 2026
Victory Capital Management Inc.5.96%4,837,5731.71BJun 29, 2026
State Street Corporation4.81%3,907,6561.38BJun 29, 2026
Vanguard Portfolio Management LLC4.53%3,678,7981.30BJun 29, 2026
Boston Partners3.76%3,051,6901.08BJun 29, 2026

Fund ownership

LH fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.21%2,603,810921.62MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.62%2,124,615752.01MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Mid-Cap Index Fund2.19%1,776,838628.91MJun 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund1.80%1,462,400517.62MAug 30, 2026
Victory Portfolios-Victory Sycamore Established Value Fund1.78%1,445,000511.46MJun 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.33%1,080,629382.49MSep 29, 2026